Insulin Management in Gestational Diabetes

Preferred Insulin Types

The American College of Obstetricians and Gynecologists recommends insulin lispro and insulin aspart as the preferred rapid-acting insulins for gestational diabetes, as they have been studied in randomized controlled trials and demonstrate safety in pregnancy 1
The American Diabetes Association suggests that insulin detemir and NPH insulin are the preferred long-acting options for basal coverage 1
NPH insulin remains an acceptable alternative, particularly in resource-limited settings or when cost is a concern 1
Insulin glargine can be considered acceptable despite limited randomized trial data, particularly for women already well-controlled on this regimen pre-pregnancy 1, 2

Initial Dosing Strategy

Calculate total daily insulin dose as 0.5 units/kg/day based on current body weight, with a division of 50% basal insulin and 50% prandial insulin distributed across three meals 1
Both multiple daily injections and continuous subcutaneous insulin infusion are equally acceptable, with neither shown to be superior 1, 2

Titration and Monitoring Requirements

The American Diabetes Association recommends fasting glucose targets of 70-95 mg/dL and one-hour postprandial targets of 110-140 mg/dL 2, 3
Perform blood glucose monitoring 4-6 times daily to guide insulin dose adjustments 2
Monitor A1C monthly with a target <6% if achievable without significant hypoglycemia, or <7% if needed to prevent hypoglycemia 4, 5

Critical Clinical Pitfalls

A rapid reduction in insulin requirements may indicate placental insufficiency and requires immediate obstetric evaluation 2, 3
Provide comprehensive education on hypoglycemia prevention, recognition, and treatment to patients and family members before initiating insulin 2, 6

Postpartum Considerations

Insulin requirements drop precipitously after placental delivery, and resume insulin at either 80% of pre-pregnancy doses or 50% of end-of-pregnancy doses immediately postpartum 2
Close monitoring is required in the immediate postpartum period to prevent hypoglycemia 6

Specialized Care Recommendation

Due to the complexity of insulin management in pregnancy, referral to a specialized diabetes and pregnancy center offering team-based care is strongly recommended for optimal maternal and fetal outcomes 2, 6

Insulin Management in Pregnancy

Glycemic Targets and Titration

The American Diabetes Association recommends a 2-hour postprandial glucose target of <120 mg/dL (6.7 mmol/L) 7

Insulin Requirements and Adjustments

During the first trimester (weeks 10-16), insulin requirements decrease by 12% due to decreased blood glucose levels and risk of hypoglycemia 8
In the second and third trimester (weeks 17-36), insulin resistance develops, requiring up to 2-3 fold increases in total daily dose 8
After 28 weeks gestation, insulin needs rise by approximately 62% from early pregnancy levels 8
Immediately after delivery, insulin requirements drop dramatically, and resuming insulin at either 80% of pre-pregnancy doses or 50% of end-of-pregnancy doses is recommended to prevent postpartum hypoglycemia 8

Patient Education and Safety

The American College of Obstetricians and Gynecologists recommends providing comprehensive hypoglycemia education before initiating Humalog, as pregnant patients with type 1 diabetes have increased hypoglycemia risk in the first trimester and altered counter-regulatory responses 9

Specialized Care

Referral to a specialized diabetes and pregnancy center with team-based care is strongly recommended for optimal outcomes 9

Evidence‑Based Glycemic Management in Gestational Diabetes

Glycemic Targets for Titration

The American Diabetes Association (ADA) recommends a fasting plasma glucose target of < 95 mg/dL (5.3 mmol/L) during pregnancy. 10
The ADA recommends a 1‑hour post‑prandial glucose target of < 140 mg/dL (7.8 mmol/L). 10
The ADA recommends a 2‑hour post‑prandial glucose target of < 120 mg/dL (6.7 mmol/L). 10

Insulin Requirement Trends Across Trimesters

According to the ADA, insulin requirements increase 2–3‑fold during the second and third trimesters as placental hormones induce progressive insulin resistance. 10

A1C Monitoring Guidance

The ADA advises a monthly A1C target of < 6 % (42 mmol/mol) when this can be achieved without significant hypoglycemia; if hypoglycemia risk is high, the target may be relaxed to < 7 % (53 mmol/mol). 10

Insulin Management and Glucose Targets in Pregnancy

Glucose Targets for Insulin‑Treated Pregnant Women

The American Diabetes Association (ADA) recommends for women with pre‑existing type 1 or type 2 diabetes a fasting/pre‑meal glucose of 70–95 mg/dL (3.9–5.3 mmol/L), a 1‑hour post‑prandial glucose of 110–140 mg/dL (6.1–7.8 mmol/L), a 2‑hour post‑prandial glucose of 100–120 mg/dL (5.6–6.7 mmol/L), and an A1C < 6 % (42 mmol/mol) when achievable without significant hypoglycemia (relax to < 7 % if needed) 11.
The lower fasting limit of 70 mg/dL applies only to insulin‑treated patients to avoid hypoglycemia and is not applied to diet‑controlled type 2 diabetes 11.
For women with insulin‑requiring gestational diabetes, the ADA sets a 1‑hour post‑prandial target of 110–140 mg/dL and a 2‑hour post‑prandial target of 100–120 mg/dL 12.
When glucose targets cannot be met without significant hypoglycemia, the ADA advises using individualized, less stringent targets, especially for patients with a history of recurrent hypoglycemia or hypoglycemia unawareness 11.

Monitoring Recommendations

The ADA recommends pre‑prandial self‑monitoring of blood glucose (SMBG) for patients using insulin pumps or basal‑bolus regimens so that rapid‑acting insulin doses can be appropriately adjusted 11.

Insulin Dose Adjustments During Pregnancy

According to the ADA, insulin resistance rises markedly in the second and third trimesters (weeks 17–36), necessitating a 2–3‑fold increase in total daily insulin dose; overall insulin requirements typically increase by ≈5 % per week through week 36 11.

Post‑Delivery Insulin Management

The Anaesthesia Society (based on 2018 recommendations) states that immediately after delivery insulin needs fall sharply; clinicians should resume insulin at 80 % of the pre‑pregnancy dose or 50 % of the end‑of‑pregnancy dose 13.
For type 1 diabetes postpartum, basal insulin must not be discontinued to prevent ketoacidosis 13.
For type 2 diabetes postpartum, insulin should be continued at roughly half the pre‑delivery dose while awaiting specialist guidance 13.
For gestational diabetes postpartum, insulin should be stopped, and blood glucose should be checked before meals and 2 hours after meals for 48 hours to ensure safe glycemic control 13.

Insulin Management in Pregnancy for Women with Pre‑existing Diabetes

Regimen Transition

Transition from premixed insulin (e.g., NovoMix) to a basal‑bolus regimen using rapid‑acting insulin aspart for meals and NPH or insulin detemir for basal coverage is recommended for pregnant women with pre‑existing diabetes. 14, 15
Premixed insulin is suboptimal in pregnancy because it does not permit the flexible dose adjustments required as insulin needs change rapidly throughout gestation. 16

Glycemic Targets

Target fasting/pre‑meal glucose 70–95 mg/dL (3.9–5.3 mmol/L); 1‑hour post‑prandial 110–140 mg/dL (6.1–7.8 mmol/L); 2‑hour post‑prandial 100–120 mg/dL (5.6–6.7 mmol/L). 16, 15
Recommended A1C goal is < 6 % (42 mmol/mol) if achievable without significant hypoglycemia; otherwise aim for < 7 % (53 mmol/mol). 16

Insulin Dose Adjustments Across Trimesters

First trimester: Women are at the highest risk for hypoglycemia; close glucose monitoring and proactive dose reductions are essential. 14, 15
Second and third trimesters (≈ week 16 onward): Insulin resistance rises markedly, with insulin requirements increasing ~5 % per week through week 36, often resulting in a total daily dose that doubles or triples compared with pre‑pregnancy levels. 16
Late third trimester (≥ week 36): Insulin needs may plateau or decline slightly; an abrupt, unexplained reduction may indicate placental insufficiency and warrants immediate obstetric evaluation. 16

Safety Considerations

Comprehensive education on hypoglycemia prevention, recognition, and treatment for the patient and family is essential before, during, and after pregnancy. 14, 15
Pregnancy attenuates counter‑regulatory hormone responses, reducing awareness of hypoglycemia. 14, 15
Diabetic ketoacidosis can develop at relatively low glucose levels (< 200 mg/dL) in pregnancy and carries a high risk of stillbirth; urgent emergency care is required. 14
Rapid implementation of tight glycemic control may exacerbate diabetic retinopathy; a dilated eye examination should be performed in the first trimester and repeated throughout pregnancy. 14, 15, 16

Adjunctive Therapies

Low‑dose aspirin 81 mg daily should be started by the end of the first trimester (ideally by 12 weeks) to reduce the risk of preeclampsia. 14, 15

Postpartum Management

Insulin requirements fall sharply immediately after delivery; resume insulin at approximately 80 % of pre‑pregnancy doses or 50 % of end‑of‑pregnancy doses to avoid severe hypoglycemia. 14, 15
Intensive glucose monitoring is required for the first 48 hours postpartum.

Multidisciplinary Care

Referral to a specialized diabetes‑in‑pregnancy center with a multidisciplinary team (maternal‑fetal medicine, endocrinology, diabetes education, nutrition) is strongly recommended to manage the complex insulin adjustments required during pregnancy. 16

Insulin Management for Elevated Fasting Glucose in Pregnancy

Glycemic Targets

Basal Insulin Dose Adjustment

Titration Algorithm

Monitoring Requirements

Prandial Insulin Coverage

Red‑Flag Situations Requiring Urgent Evaluation

Referral and Multidisciplinary Care

Management of Steroid‑Induced Hyperglycemia in Pregnant Patients with Type 1 Diabetes

Metabolic Risks in Pregnancy

Pregnancy creates a ketogenic metabolic environment, and individuals with pre‑existing type 1 diabetes are susceptible to diabetic ketoacidosis at lower blood‑glucose thresholds than when non‑pregnant, increasing the risk of severe metabolic decompensation during steroid therapy. 20

Insulin Adjustment Recommendations

After antenatal corticosteroid administration, insulin doses should be increased by 2–4 units every 2–3 days, guided by capillary glucose monitoring, with targets of fasting glucose 70–95 mg/dL and 1‑hour post‑prandial glucose < 140 mg/dL to maintain euglycemia throughout the steroid exposure period. 21

Prandial Insulin Management for Pregnant Women with Diabetes

Glycemic Targets During Pregnancy

In pregnant women, the recommended 1‑hour post‑prandial glucose target is 110–140 mg/dL, and the 2‑hour target is 100–120 mg/dL; values above these thresholds indicate the need for prandial insulin adjustment. 22
Fasting glucose should be maintained between 70–95 mg/dL; values above 95 mg/dL on consecutive days trigger consideration of basal insulin increase. 22

Prandial Insulin Adjustment Strategy

Increase the carbohydrate‑to‑insulin ratio by approximately 20 % (e.g., from 1 U per 6 g carbohydrate to 1 U per 5 g) for meals where 1‑hour post‑prandial glucose exceeds 140 mg/dL. 22
Titrate the ratio every 2–3 days, progressively tightening (e.g., 1:4.5, then 1:4), until post‑prandial values consistently fall below the 140 mg/dL threshold. 22
During weeks 17–36 of gestation, insulin resistance rises exponentially, with total insulin requirements typically increasing by ~5 % per week and potentially doubling or tripling by week 36. 22

Monitoring Requirements

Perform self‑monitoring of blood glucose 4–6 times daily (fasting, pre‑meal, and 1‑hour post‑meal) to guide insulin titration. 22
Obtain a monthly A1C measurement, aiming for <6 % if achievable without significant hypoglycemia; a target of <7 % is acceptable when hypoglycemia risk is higher. 22

Safety and Clinical Considerations

Provide comprehensive hypoglycemia education to the patient and family, as pregnancy attenuates counter‑regulatory hormone responses and heightens hypoglycemia risk, especially in early gestation. 22
An abrupt, unexplained reduction in insulin requirements may indicate placental insufficiency and warrants immediate obstetric evaluation. 22
Insulin glargine is considered acceptable for use during pregnancy despite limited randomized trial data, particularly for women already well‑controlled on this basal regimen before conception. 22 (strength of evidence: limited, expert consensus)

Multidisciplinary Care Recommendation

Refer pregnant patients with diabetes to a specialized diabetes‑and‑pregnancy center that integrates maternal‑fetal medicine, endocrinology, diabetes education, and nutrition services to manage complex insulin adjustments. 22 (strength of recommendation: strong, based on clinical consensus)

Insulin Initiation Criteria for Gestational Diabetes

Indications for Starting Insulin Therapy

In pregnant women diagnosed with gestational diabetes, initiate insulin therapy when fasting plasma glucose remains ≥ 95 mg/dL or 1‑hour post‑prandial glucose remains ≥ 140 mg/dL despite 1–2 weeks of medical nutrition therapy and exercise, as recommended by the Diabetes Care guideline (2018) 23.

Insulin Therapy for Hyperglycemia in Pregnancy

Therapeutic Recommendations

Insulin should be added promptly because metformin alone does not achieve glycemic targets in pregnant patients with elevated evening glucose. 24
Insulin is the preferred first‑line pharmacologic treatment for hyperglycemia in pregnancy due to minimal placental transfer and the most extensive safety record. 25, 26, 24
Metformin is not recommended as first‑line therapy in pregnancy because it crosses the placenta, achieving fetal cord concentrations comparable to or higher than maternal levels, and long‑term offspring safety data are lacking. 25, 26, 24

Glycemic Targets

Recommended glucose targets during pregnancy are:
- Fasting 70–95 mg/dL
- 1‑hour post‑prandial 110–140 mg/dL
- 2‑hour post‑prandial 100–120 mg/dL

Monitoring Guidance

Hemoglobin A1C should be measured monthly with a goal < 6 % when achievable without significant hypoglycemia, or < 7 % if hypoglycemia risk is high; however, A1C is a secondary metric and cannot replace frequent self‑monitoring of glucose, which better captures post‑prandial excursions linked to fetal macrosomia. 25

Clinical Pitfalls to Avoid

Do not delay insulin initiation when evening glucose remains markedly elevated (e.g., ~200 mg/dL), as postponing escalation after metformin failure leads to inadequate glycemic control. 24
Do not rely solely on fasting glucose values; post‑prandial glucose is the primary determinant of fetal overgrowth and must be controlled. 25

Management of Carrier Fluids and Glycemic Control in Diabetic Pregnancy Receiving Magnesium Sulfate

Glycemic Targets and Physiologic Insulin Resistance

The recommended glucose targets for pregnant patients with overt diabetes are fasting 70–95 mg/dL, 1‑hour post‑prandial 110–140 mg/dL, and 2‑hour post‑prandial 100–120 mg/dL throughout pregnancy (American Diabetes Association guideline) 27.
At 31 weeks gestation, physiological insulin resistance increases insulin requirements by approximately 2–3 fold; adding exogenous glucose via a dextrose‑containing carrier fluid further worsens glycemic control (Diabetes Care 2024) 27.

Risks of Dextrose‑Containing Carrier Fluids

Continuing D5W as the carrier for magnesium sulfate introduces a continuous glucose load that opposes the above targets and is therefore contraindicated in diabetic pregnancy (Diabetes Care 2024) 27.

Intrapartum Glucose Monitoring During Magnesium Sulfate Therapy

Capillary glucose should be measured every 1–2 hours while the patient receives magnesium sulfate, with an intrapartum target range of 80–110 mg/dL (Anaesthesia 2018) 28.

Maternal hyperglycemia during labor triggers fetal hyperinsulinism, resulting in a 10–40 % incidence of neonatal hypoglycemia (Anaesthesia 2018) 28.
Maintaining intrapartum maternal glucose within 80–110 mg/dL reduces the risk of neonatal hypoglycemia and fetal hypoxia (Anaesthesia 2018) 28.

Post‑Delivery Insulin Adjustment

After placental delivery, maternal insulin requirements fall sharply; insulin should be resumed at roughly 50 % of the late‑pregnancy dose (or 80 % of the pre‑pregnancy dose) to prevent severe maternal hypoglycemia (Anaesthesia 2018) 28.